Study summary · research use only
Kisspeptin in the Prediction of Pregnancy Complications
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review discusses kisspeptin and its receptor as potential biomarkers of pregnancy complications in humans. The abstract describes kisspeptin as a regulator of gonadotrophin releasing hormone (GnRH) neuronal function and reports it is also expressed in syncytiotrophoblasts, with its receptor in both cyto- and syncytio-trophoblasts, playing a role in placentation. It states circulating kisspeptin rises during healthy pregnancy and has been proposed as a biomarker of placental function, and that altered kisspeptin levels are associated with increased risk of adverse maternal and fetal complications, summarizing data on kisspeptin as a putative biomarker for miscarriage, ectopic pregnancy (EP), preterm birth (PTB), fetal growth restriction (FGR), hypertensive disorders of pregnancy (HDP), pre-eclampsia (PE), gestational diabetes mellitus (GDM), and gestational trophoblastic disease (GTD).
Abstract
Kisspeptin and its receptor are central to reproductive health acting as key regulators of the reproductive endocrine axis in humans. Kisspeptin is most widely recognised as a regulator of gonadotrophin releasing hormone (GnRH) neuronal function. However, recent evidence has demonstrated that kisspeptin and its receptor also play a fundamental role during pregnancy in the regulation of placentation. Kisspeptin is abundantly expressed in syncytiotrophoblasts, and its receptor in both cyto- and syncytio-trophoblasts. Circulating levels of kisspeptin rise dramatically during healthy pregnancy, which have been proposed as having potential as a biomarker of placental function. Indeed, alterations in kisspeptin levels are associated with an increased risk of adverse maternal and foetal complications. This review summarises data evaluating kisspeptin's role as a putative biomarker of pregnancy complications including miscarriage, ectopic pregnancy (EP), preterm birth (PTB), foetal growth restriction (FGR), hypertensive disorders of pregnancy (HDP), pre-eclampsia (PE), gestational diabetes mellitus (GDM), and gestational trophoblastic disease (GTD).
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.